Clinical guideline
NCCN Guidelines® Insights: Esophageal and Esophagogastric Junction Cancers, Version 4.2026
J Natl Compr Canc Netw · 2026
Studies and guidelines: Oesophageal cancer
20 items with a structured summary · Oesophageal cancer: the complete guide
Clinical guideline
ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma
ESMO Open · 2025
Clinical guideline
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2023
Clinical trial · Phase 3
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study
ESMO Open · 2025
12.3 vs 9.8 monthsMedian overall survival
Clinical trial · Phase 3
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
N Engl J Med · 2025
57.4% vs 50.7%3-year overall survival
Clinical trial · Phase 3
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial
Lancet · 2024
72.1% vs 62.6%3-year overall survival, NeoCF+D vs NeoCF
Observational study
Improvement of esophageal cancer survival in Northeast Iran: A two-decade journey in a high-risk, low- resource region
PLoS ONE · 2024
340 deathsNumber of deaths
Other
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020
Gastroenterology · 2022
604,100 casesNew cases of oesophageal cancer in 2020 (worldwide)
Clinical trial · Phase 3
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
N Engl J Med · 2021
22.4 vs 11.0 monthsMedian disease-free survival
Clinical trial
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
JCO · 2021
147 monthsMedian follow-up
Observational study
A prospective study of tea drinking temperature and risk of esophageal squamous cell carcinoma
Int J Cancer · 2020
HR 1.41Measured temperature 60 °C or higher vs below 60
Other
Carcinogenicity of opium consumption
The Lancet Oncology · 2020
Observational study
Individual and Combined Effects of Environmental Risk Factors for Esophageal Cancer Based on Results From the Golestan Cohort Study
Gastroenterology · 2019
HR 1.85Opium smoking
Review article
Oesophageal cancer
Nat Rev Dis Primers · 2017
Clinical trial · Phase 3
Preoperative chemoradiotherapy for esophageal or junctional cancer
N Engl J Med · 2012
49.4 vs 24.0 monthsMedian overall survival
Other
Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study
BMJ · 2009
98% of participantsRegular black tea drinking (cohort)
Observational study
Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma
N Engl J Med · 1999
7.7Odds ratio of oesophageal adenocarcinoma in people with recurrent reflux symptoms versus those without symptoms
Clinical trial · Phase 3
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648
Annals of Oncology · 2026
HR 0.62Overall survival (OS) in PD-L1 ≥1%: nivolumab + chemotherapy vs chemotherapy
Clinical trial · Phase 3
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
N Engl J Med · 2022
15.4 vs 9.1 monthsMedian overall survival, nivolumab + chemotherapy (PD-L1 ≥1%)
Clinical trial · Phase 3
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Lancet · 2021
13.9 vs 8.8 monthsMedian overall survival, squamous with CPS ≥10
Nothing found.